<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05616689</url>
  </required_header>
  <id_info>
    <org_study_id>RDO KPNC 20 - 008</org_study_id>
    <nct_id>NCT05616689</nct_id>
  </id_info>
  <brief_title>Bundled Hyperpolypharmacy Deprescribing</brief_title>
  <official_title>Bundled Hyperpolypharmacy Deprescribing: Implementation and Evaluation of a System-wide Quality Improvement Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaiser Permanente</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaiser Permanente</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Older patients using many prescription drugs (hyperpolypharmacy) may be at increased risk of&#xD;
      adverse drug effects. This randomized controlled trial tested the effectiveness and safety of&#xD;
      a quality intervention intended to reduce hyperpolypharmacy. The study was set at Kaiser&#xD;
      Permanente Northern California, an integrated health system with multiple pre-existing&#xD;
      deprescribing workflows. Eligible patients were aged ≥76 years using ≥10 prescription&#xD;
      medications. The intervention included physician-pharmacist collaborative drug therapy&#xD;
      management, standard-of-care practice recommendations, shared decision-making, and&#xD;
      deprescribing protocols administered by telephone over multiple cycles for a maximum of 180&#xD;
      days after allocation. A priori primary effectiveness endpoints included change in the number&#xD;
      of medications and in the prevalence of geriatric syndrome from 181-365 days after&#xD;
      allocation. Second endpoints included utilization and adverse drug withdrawal effects.&#xD;
      Information was obtained from the electronic health record.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 19, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Actual">July 29, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in prevalence of geriatric syndrome</measure>
    <time_frame>Difference between (days 181-365 after randomization) and (180 days before randomization)</time_frame>
    <description>Change in prevalence for any of the following: Falls (hip fracture, lower leg fracture, osteoporosis with fracture, pathologic fracture, osteonecrosis; gait; repeated falls; syncope; tripping; reduced mobility), Cognition (Somnolence; awareness; dizziness; malaise; Urinary incontinence (Unspecified urinary incontinence; retention of urine, unspecified; functional urinary incontinence; stress incontinence ; other specified urinary incontinence) and Pain (Drug induced headache; joint pain; muscle weakness, rhabdomyolysis, spas; myalgia)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in number of medications</measure>
    <time_frame>Difference between (days 181-365 after randomization) and (180 days before randomization)</time_frame>
    <description>Change in number of dispensed medications recorded in the comprehensive, integrated pharmacy information system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Utilization</measure>
    <time_frame>Difference between (days 181-365 after randomization) and (180 days before randomization)</time_frame>
    <description>Change in number of outpatient visits, inpatient visits, and emergency department visits.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse drug withdrawal effects</measure>
    <time_frame>Difference between (days 181-365 after randomization) and (180 days before randomization)</time_frame>
    <description>Change in prevalence of lower respiratory, cardiovascular, gastrointestinal, hyperuricemia, and elevated blood glucose</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2471</enrollment>
  <condition>Polypharmacy</condition>
  <arm_group>
    <arm_group_label>Bundled hyperpolypharmacy intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants with physician authorization who are randomly assigned to intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Eligible participants with physician authorization who are randomly assigned to usual care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bundled hyperpolypharmacy</intervention_name>
    <description>Bundled hyperpolypharmacy playbook to be used by pharmacist, with physician approval, in shared decision making with participant,</description>
    <arm_group_label>Bundled hyperpolypharmacy intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Kaiser Permanente patients&#xD;
&#xD;
          -  Age ≥76 years&#xD;
&#xD;
          -  ≥10 drugs (excluding topicals) where&#xD;
&#xD;
               -  drug filled ≥2 times in the past year and&#xD;
&#xD;
               -  drug last filled &lt; 180 days ago&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  less than 12 months preceding enrollment at Kaiser Permanente&#xD;
&#xD;
          -  no primary care practitioner assigned&#xD;
&#xD;
          -  on dialysis&#xD;
&#xD;
          -  history of heart, liver, lung, breast, or bone marrow transplant&#xD;
&#xD;
          -  in hospice&#xD;
&#xD;
          -  under active treatment for cancer during the past 12 months&#xD;
&#xD;
          -  has received an intervention through the Pharmacy Targeted Deprescribing Program in&#xD;
             the preceding year.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>76 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Herrinton, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaiser Permanente</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaiser Permanente Division of Research</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>October 19, 2022</study_first_submitted>
  <study_first_submitted_qc>November 14, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2022</study_first_posted>
  <last_update_submitted>November 14, 2022</last_update_submitted>
  <last_update_submitted_qc>November 14, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>deprescribing</keyword>
  <keyword>polypharmacy</keyword>
  <keyword>drug safety</keyword>
  <keyword>randomized controlled trial</keyword>
  <keyword>pharmacist</keyword>
  <keyword>shared decision making</keyword>
  <keyword>optimal prescribing</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

